Leitlinien der Deutschen Gesellschaft für Neurologie und der Deutschen Schlaganfallgesellschaft zur Primär- und Sekundärprävention des Schlaganfalls: Aktualisierung 2007

Zusammenfassung

Im Jahr 2005 veröffentlichten die Deutsche Gesellschaft für Neurologie und die Deutsche Schlaganfallgesellschaft Leitlinien zur Primär- und Sekundärprävention des Schlaganfalls. In der Zwischenzeit hat sich aber durch eine Vielzahl neuer Studien die Notwendigkeit ergeben die Leitlinien zu aktualisieren.

Abstract

In 2005 the German Neurological Society and the German Stroke Society published recommendations for the primary and secondary prevention of stroke. In the meantime the results from many randomised trials became available. This leads to the necessity to update the recommendations.

Literatur

• 1 Diener H, Allenberg J-R, Bode C. et al .Primär- und Sekundärprävention der zerebralen Ischämie. In: Diener H, Putzki N, Berlit P et al. (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. 3. aktualisierte und erweiterte Auflage. Stuttgart; Thieme 2005: 192-214
• 2 Pi-Sunyer F X, Aronne L J, Heshmati H M. et al . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.  JAMA. 2006;  295 761-775
• 3 Despres J P, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.  N Engl J Med. 2005;  353 2121-2134
• 4 Connolly S, Pogue J, Hart R. et al. (ACTIVE Writing Group on behalf of the ACTIVE Investigators) . Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.  Lancet. 2006;  367 1903-1912
• 5 The ESPRIT Study Group . Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.  Lancet. 2006;  367 1665-1673
• 6 Diener H C, Cuhna L, Forbes C. et al (European Stroke Prevention Study 2.) . Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.  J Neurol Sci. 1996;  143 1-13
• 7 Bhatt D L, Topol E J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.  Am Heart J. 2004;  148 263-268
• 8 Diener H C, Bogousslavsky J, Brass L M. et al . Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.  Lancet. 2004;  364 331-337
• 9 Mas J L. et al., for the EVA-3S Investigators . Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis.  N Engl J Med. 2006;  355 1660-1671
• 10 The Space Collaborative Group . 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial.  Lancet. 2006;  368 1239-1247
• 11 Amarenco P, Labreuche J, Lavallee P, Touboul P. Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis.  Stroke. 2004;  35 2902-2909
• 12 The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators . High-dose atorvastatin after stroke or transient ischemic attack.  N Engl J Med. 2006;  355 549-559
• 13 Collins R, Armitage J, Parish S. et al., Heart Protection Study Collaborative Group . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions.  Lancet. 2004;  363 757-767
• 14 Bonaa K H, Njolstad I, Ueland P M. et al . Homocysteine lowering and cardiovascular events after acute myocardial infarction.  N Engl J Med. 2006;  354 1578-1588
• 15 The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators . Homocysteine lowering with folic acid and B vitamins in vascular disease.  N Engl J Med. 2006;  354 1567-1577
• 16 Toole J F, Malinow M R, Chambless L E. et al . Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.  JAMA. 2004;  291 565-575